Immunoprophylactic intervention in chemical toxicity and carcinogenicity

Veterinary and Human Toxicology

Volumn 39, Issue 1, 1997, Pages 37-43

  Silbart, Lawrence K ^a   Rasmussen, Max V ^a   Oliver, Alfred R ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; ENVIRONMENTAL CHEMICAL; TOXIC SUBSTANCE; VACCINE;

CARCINOGENICITY; DRUG RESEARCH; IMMUNOPROPHYLAXIS; INTOXICATION; MALIGNANT NEOPLASTIC DISEASE; REVIEW; TOXICITY; VACCINATION;

ANIMALS; ANTIBODY AFFINITY; CARCINOGENS, ENVIRONMENTAL; HUMANS; IMMUNIZATION; NEOPLASMS;

EID: 0031030615     PISSN: 01456296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Scherrmann JM, Terrien N, Urtizberea M et al: Immunotoxicotherapy: Present status and future trends. Clinical Toxicol 27: 1-35, 1989.
2. Sabouraud A, Scherrmann JM: Immunotherapie des intoxications medicamenteuses. Therapie 49: 41-48, 1994.
3. Butler VP: Antibodies as specific antagonists of toxins, drugs, and hormones. Pharmacol Rev 34: 109-114, 1982.
4. Colburn WA: Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab Rev 11: 223-262, 1980.
5. Sullivan JB: Immunotherapy in the poisoned patient: Overview of present applications and trends. Med Tox 1: 47-60, 1986.
6. Grabenstein JD: Immunoantidotes: III. Antichemical, antidigoxin, and other antibodies. Hosp Pharm 27: 786-796, 1992.
7. Landsteiner K: The specificity of serological reactions. Dover Publications Inc, New York: 1962.
8. Schmidt DH, Butler Jr VP: Immunological protection against digoxin toxicity. J Clin Invest 50: 866-871, 1971.
9. Schmidt DH, Kaufman BM, Butler Jr VP: Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten. J Exp Med 139: 278-292, 1974.
10. Rong KT, Zhang LJ: Immunologic protection against VX intoxication in experimental animals. Pharmacol Toxicol 67: 255-259, 1990.
11. Scherrmann J, Urtizberea M, Pierson P et al: The effect of colchicine-specific active immunization on colchicine toxicity and disposition in the rabbit. Toxicology 56: 213-222, 1989.
12. Nagao M, Takatori T, Wu B et al: Immunotherapy for the treatment of acute paraquat poisoning. Human Toxicol 8: 121-123, 1989.
13. Cadot R, Descotes J, Grenot C et al: Increased plasma paraquat levels in intoxicated mice following antiparaquat F(ab')2 treatment. J Immunopharmacol 7: 467-477, 1985.
14. Terrien N, Urtizberea M, Scherrmann J: Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol 104: 504-510, 1990.
15. Brunn GJ, Keyler DE, Ross CA et al: Drug-specific F(ab')2 fragment reduces desipramine cardiotoxicity in rats. Int J Immunopharmac 13: 841-851, 1991.
16. Pentel PR, Keyler DE, Brunn J et al: Redistribution of tricyclic andidepressants in rats using a drug-specific monoclonal antibody: Dose-response relationship. Drug Metab Dispos 19: 24-28, 1989.
17. Hickey AR, Wenger TL, Carpenter VP et al: Digoxin immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 17: 590-598, 1991.
18. Watson JF, Butler Jr VP: Biologic activity of digoxin-specific antisera. J Clin Invest 51: 638-648, 1972.
19. Colburn WA, White CM: Effect of specific antisera on the redistribution of chlorinated biphenyls in the mouse. Life Sci 24: 169-176, 1979.
20. Ochs HR, Smith TW: Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. J Clin Invest 60: 1303-1313, 1977.
21. Luster MI, Albro PW, Faith RE et al: Inability of passive antibodies to reverse the effects of dioxin toxicity. Chemos No 1: 29-34, 1978.
22. Wright AF, Green TP, Robson RT et al: Specific polyclonal and monoclonal antibody prevents paraquat accumulation into rat lung slices. Biochem Pharmacol 36: 1325-1331, 1987.
23. Butler GC, Harington CR, Yuill ME: Studies in synthetic immunochemistry: Observations on antisera against aspirin-protein complexes. Biochem J 34: 838-845, 1940.
24. Lomax P, Gross SJ, Campbell C: Immunological blockade of the hypothermic effect of delta-9 tetrahydrocannabinol in the rat. In Schonbaum E, Lomax P eds: The Pharmacology of Thermoregulation. Karger, Basel: 488-490, 1973.
25. Cerreta KV, Flynn EJ, Spector S: Pharmacological response to pentobarbital in passively immunized mice. Eur J Pharm 54: 365-371, 1979.
26. Lomax P, Campbell C, Gross SJ et al: Immunological blockade of the analgesic effect of morphine in the rat. West Pharmacol Soc Proc 16: 252-256, 1973.
27. Berkowitz B, Spector S: Evidence for active immunity to morphine in mice. Science 178: 1290-1292, 1972.
28. Berkowitz BA, Ceretta KV, Spector S: Influence of active and passive immunity on the disposition of dihydromorphine-H3. Life Sci 15: 1017-1028, 1974.
29. Rocio M, Carrera A, Ashley JA et al: Suppression of psychoactive effects of cocaine by active immunization. Nature 378: 727-730, 1995.
30. Bonese KF, Wainer BH, Fitch FW et al: Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 252: 708-710, 1974.
31. Doherty JE: Digoxin antibodies and digitalis intoxication. Editorial. N Engl J Med 307: 1398-1399, 1982.
32. Creech HJ, Franks WR: Compounds synthesized from proteins and carcinogenic hydrocarbons. Am J Cancer 30:555-562, 1937.
33. Franks WR, Creech HJ: Chemoantigens and carcinogenesis: I. Am J Cancer 35: 203-212, 1939.
34. Peck RM, Peck EB: Inhibition of chemically induced neoplasia by immunization with an antigenic carcinogen-protein conjugate. Cancer Res 31: 1550-1554, 1971.
35. Peck RM, Tan TK, Peck EB: Pulmonary carcinogenesis by derivatives of polynuclear aromatic alkylating agents. Cancer Res 36: 2423-2427, 1976.
36. Homburger F, Tregier A: Modifying factors in carcinogenesis. Prog Exp Tumor Res 1: 311-328, 1960.
37. Curtis GL, Ryan WL, Stenback F: Antibody stimulation of benzo-(a)pyrene carcinogenesis. Cancer Lett 4: 223-228, 1978.
38. Moolten FL, Schreiber B, Rizzone A et al: Protection of mice against 7,12-dimethylbenz(a)anthracene-induced skin tumors by immunization with a fluorinated analog of the carcinogen. Cancer Res 41: 425-429, 1981.
39. Moolten FL, Capparell NJ, Boger E et al: Induction of antibodies against carcinogenic polycyclic aromatic hydrocarbons. Nature 272: 614-616, 1978.
40. McKenzie SJ, Halsey JF: Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133: 1818-1824, 1984.
41. Silbart LK, Nordblom G, Keren DF et al: A rapid and sensitive screening method for the detection of anti-2-acetylaminofluorene immunoglobulins. J Immunol Methods 109: 103-112, 1988.
42. Silbart LK, Keren DF: Reduction of intestinal carcinogen absorption by carcinogen-specific secretory immunity. Science 243: 1462-1464, 1989.
43. Silbart LK, Keren DF, McDonald RA et al: Characterization of the mucosal immune response to 2-acetylaminofluorene-protein conjugates. Reg Immunol 4: 245-254, 1992.
44. Silbart LK, McAleer F, Rasmussen MV et al: Selective induction of mucosal immune responses to 2-acetylaminofluorene. Anticancer Res 16: 651-660, 1996.
45. Childers NK, Michalek SM, Denys F et al: Characterization of liposomes for oral vaccines. Adv Exp Med Biol 216: 1771-1780, 1987.
46. Gregory RL, Michalek SM, Richardson G et al: Characterization of immune response to oral administration of Streptococcus sobrinus ribosomal preparations in liposomes. Infect Immun 54: 780-786, 1986.
47. Jackson S, Mestecky J, Childers NK et al: Liposomes containing anti-idiotypic antibodies: An oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces. Infect Immun 58: 1932-1936, 1990.
48. Alpar HO, Bowen JC, Brown MRW: Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int J Pharm 88: 335-344, 1992.
49. Antimisiaris SG, Jayasekera P, Gregoriadis G: Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant vesicles. J Immunol Methods 166: 271-280, 1993.
50. Almeida AJ, Alpar HO, Williamson D et al: Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin B subunit. Biochem Soc Trans 20: 316S, 1992.
51. Edelman R, Russell RG, Losonsky G et al: Immunization of rabbits with enterotoxigenic E coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 11: 155-158, 1993.
52. Trudel M, Nadon F, Seguin C et al: Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10: 107-112, 1992.
53. Moolten F, Capparell N, Boger E: Reduction of respiratory tract binding of benzo(a)pyrene in mice by immunization. J Natl Cancer Inst 61: 1347-1349, 1978.
54. Elson CO, Ealding W: Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132: 2736-2741, 1984.
55. 1. Ann NY Acad Sci 778: 422-424, 1996.
56. Stok W, Van Der Heijden PJ, Bianchi AT: Conversion of orally induced suppression of the mucosal immune response to ovalbumin into stimulation by conjugating ovalbumin to cholera toxin or its B subunit. Vaccine 12: 521-526, 1994.
57. Harris CC, Vahakangas K, Newman MJ et al: Detection of benzo(a)pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci USA 32: 6672-6676, 1985.
58. Haugen A, Becher G, Benestad C et al : Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a)pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 46: 4178-4183, 1986.
59. Newman MJ, Light BA, Weston A et al: Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. J Clin Invest 82: 145-153, 1988.
60. 1 in animal-feed production plant workers. Environ Health Perspect 99: 195-197, 1993.
61. Autrup H, Seremet T, Wakhisi J: Evidence for human antibodies that recognize an aflatoxin epitope in groups with high and low exposure to aflatoxins. Arch Environ Health 45: 31-34, 1990.
62. Hansen LG: Halogenated aromatic compounds. In Cockerham LG, Shane BS eds: Basic Environmental Toxicology. CRC Press Inc, Boca Raton: 199-230, 1994.
63. Lutwick LI: Relationship between aflatoxin, hepatitis-B virus, and hepatocellular carcinoma. Lancet 755-757, 1979.
64. Woqan GN: Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 52: 2114s-2118s, 1992.
65. Wild CP, Shrestha SM, Anwar WA et al: Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in the Gambia and Thailand. Toxicol Lett 64/65: 455-461, 1992.
66. 1 in chickens given feed contaminated with Aspergillus flavus and reduction of the toxicity by activated charcoal and some chemical agents. Avian Dis 28: 61-69, 1984.
67. Thaxon JP, Tung HT, Hamilton PB: Immunosuppression in chickens by aflatoxin. Poult Sci 53: 721-725, 1974.
68. Hecht SS, Hoffman D: The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surveys 8: 1989.
69. Preston-Martin S: Evaluation of the evidence that tobacco-specific nitrosamines (TSNA) cause cancer in humans. Toxicology 21: 295-298, 1991.
70. Melick WF, Naryka JJ, Kelly RE: Bladder cancer due to exposure to para-aminobiphenyl A 17-year follow-up. J Urol 106: 220-226, 1971.
71. Vineis P, Ronco G: Interindividual variation in carcinogen metabolism and bladder cancer risk. Environ Health Perspect 98: 95-99, 1992.
72. DeSerres FJ, Zeiger E, Hatch FT: Future directions and research priorities for food mutagens. Environ Health Perspect 67: 153-157, 1986.